JTCS Click here to go to SJM website.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Richard J. Battafarano
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Battafarano, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Battafarano, R. J.
Related Collections
Right arrow Lung - cancer
Right arrowRelated Article

J Thorac Cardiovasc Surg 2006;131:1227-1228
© 2006 The American Association for Thoracic Surgery

Editorial

Optimal management of patients with non–small cell lung cancer with ipsilateral mediastinal lymph node metastases

Richard J. Battafarano, MD, PhD *

Barnes-Jewish Hospital, St Louis, Mo.

Received for publication October 25, 2005; accepted for publication November 2, 2005.

* Address for reprints: Richard J. Battafarano, MD, One Barnes-Jewish Plaza, 33107 Queeny Tower, St Louis, MO 63110-1013 (Email: battafarano@msnotes.wustl.edu).

The first 20% of the full text of this article appears below.

GoThe optimal management of patients with non–small cell lung cancer with ipsilateral mediastinal lymph node metastases (N2) remains controversial. Patients with N2 disease represent a heterogeneous group that includes patients with microscopic disease in a single lymph node and patients with bulky metastatic adenopathy at multiple ipsilateral lymph node stations. Although many reports have described the feasibility of neoadjuvant therapy followed by resection in these patients, residual N2 disease at the time of resection is associated with limited survival. 1,2 Go In addition, pneumonectomy performed after neoadjuvant therapy has been associated with significant perioperative morbidity and mortality. 3,4 Go

In this issue of the Journal, Dr Cerfolio and . . . [Full Text of this Article]


Related Article

Restaging patients with N2 (stage IIIa) non–small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study
Robert James Cerfolio, Ayesha S. Bryant, and Buddhiwardhan Ojha
J. Thorac. Cardiovasc. Surg. 2006 131: 1229-1235. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The American Association for Thoracic Surgery.